comparemela.com

Page 8 - Cyte Contacts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MaxCyte to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., June 01, 2023 MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well. | June 1, 2023

United kingdomChris welshRupert deardenDavid deuchlerMary jane elliottEmma earl freddy crossleyPanmure gordonWilliam blairConsilium strategic communicationsGilmartin groupMaxcyte incAnnual growth stock conferenceWilliam blair presentationFlow electroporationCyte contactsJoint corporate

MaxCyte Signs Strategic Platform License with Walking Fish

Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious.

United kingdomDoug doerflerMary jane elliottPanmure gordonDavid deuchlerChris welshRupert deardenEmma earl freddy crossleyMaxcyte incGilmartin groupConsilium strategic communicationsWalking fish therapeutics incWalking fish therapeuticsWalking fishFlow electroporationCyte contacts

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

ROCKVILLE, Md., April 12, 2023 MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization. | April 12, 2023

United kingdomRupert deardenEmma earl freddy crossleyDavid deuchlerPanmure gordonMaxcyte incGilmartin groupFlow electroporationCyte contactsJoint corporateNc stock exchangePress releaseNd mxct us57777k1060

Investegate |MaxCyte, Inc Announcements | MaxCyte, Inc : Director/PDMR Shareholding

Investegate announcements from MaxCyte, Inc., Director/PDMR Shareholding

United kingdomUnited statesEmma earl freddy crossleyMary jane elliottRupert deardenDavid deuchlerRichard douglasPanmure gordonChris welshConsilium strategic communicationsGilmartin groupMaxcyte incUsstock exchangeCompany common stockNon executive chairmanCommon stock

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

ROCKVILLE, Md., March 27, 2023 MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization. | March 27, 2023

United kingdomDouglasj swirskyMary jane elliottRon holtzDavid deuchlerRupert deardenPanmure gordonChris welshDoug doerflerDouglas swirskyEmma earl freddy crossleyBoard of cellectar biosciences incAavantibio incExchange commission onMaxcyte incConsilium strategic communications

vimarsana © 2020. All Rights Reserved.